UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000018878
Receipt No. R000021832
Scientific Title Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis
Date of disclosure of the study information 2015/09/01
Last modified on 2019/04/01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis
Acronym clinical study for pancreatic cancer with peritoneal metastasis
Scientific Title Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis
Scientific Title:Acronym clinical study for pancreatic cancer with peritoneal metastasis
Region
Japan

Condition
Condition The patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.
Classification by specialty
Hepato-biliary-pancreatic surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To investigate safety and clinical efficacy of Gemcitabine and nab-paclitaxel plus intraperitoneal paclitaxel administration in pancreatic cancer patients with peritoneal metastasis
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes One year survival rate
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Gemcitabine (800-1000mg/m2, weekly for 3 weks with 1wk rest) and nab-paclitaxel(100-125mg/m2, weekly for 3 weks with 1wk rest) plus intraperitoneal paclitaxel administration (15-20mg/m2, weekly for 3 weks with 1wk rest)
Regimen will be continued according to the protocol.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria Pancreatic adenocarcinoma histologically proven with peritoneal metastasis diagnosed using staging laparoscopy or open laparotomy, performance status 0 or 1, adequate bone marrow function, adequate liver function, adequate renal function, obtained informed consent
Key exclusion criteria Metastasis to distant organ sites such as the liver, lungs or bone; other active concomitant malignancies; other severe medical conditions; contraindication of Gemcitabine, nab-paclitaxel or Paclitaxel, or Pregnant woman
Target sample size 48

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Sohei SATOI MD, FACS
Organization Kansai Medical University
Division name Department of Surgery
Zip code
Address 2-3-1 Shinmachi, Hirakata, Osaka
TEL 0728040101
Email satoi@hirakata.kmu.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Sohei SATOI MD, FACS
Organization Kansai Medical University
Division name Department of Surgery
Zip code
Address 2-3-1 Shinmachi, Hirakata, Osaka
TEL 0728040101
Homepage URL
Email satoi@hirakata.kmu.ac.jp

Sponsor
Institute Study group of pancreatic cancer with peritoneal metastasis
Institute
Department

Funding Source
Organization Study group of pancreatic cancer with peritoneal metastasis
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 09 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 04 Month 30 Day
Date of IRB
2015 Year 08 Month 12 Day
Anticipated trial start date
2015 Year 09 Month 01 Day
Last follow-up date
2019 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 09 Month 01 Day
Last modified on
2019 Year 04 Month 01 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021832

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.